Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Chevron Deference Muted, Higher Volume Ahead For US Supplement Market Regulatory Questions

Jul 19 2024

• By Malcolm Spicer

Related Content

US Warning Letter Summer Rerun: Delta-8 In Food Packaged Like Brands Popular With Children

Jul 16 2024

House Appropriators Develop Hazy Picture For Future Of US Hemp Products Industry

Jul 11 2024

US FDA Doubts Hemp ‘Derivatives Created From Scratch’ Belong In Lawful Use Pathway

Feb 06 2023

US FDA ‘Punt’ On Hemp Rulemaking Frustrates, Confuses Supplement Industry

Jan 27 2023

Hemp Regulation Flags Raised By States Wave Tougher Compliance Cloud Over Industry

Apr 11 2024

US FDA’s NDIN Master File Draft Guidance Notes ‘No Presumption’ To Keep Information Confidential

Apr 03 2024

Deference No More: More Challenges Against US FDA After Supreme Court Tosses Chevron Doctrine?

Jul 02 2024

Prescription Marijuana? FDA Rescheduling Memo Sets Stage To Test Whether There’s A Viable Market

Feb 14 2024

Schumer Includes Cannabinoid Pathway For Supplements In Cannabis Legalization Draft Bill

Jul 14 2021

Red Yeast Rice History Offers Blueprint For Clearing CBD As Dietary Ingredient

May 24 2019

Making Hemp Lawful As Dietary Ingredient In US Could Be More Than Marketers Bargain For

Apr 07 2022

Additional Topics

International United States US States FDA Litigation Cannabidiol CBD Business Strategies Commercial Compliance Consumer Dietary Supplements Cosmetics Drug Safety Drug Approval Standards Enforcement Ingredients Manufacturing OTC Drugs Policy Politics Regulation Safety

More from Regulation

More from Policy & Regulation

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window